The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
SwanBio Therapeutics, a US-based gene therapy developer focused on adeno-associated virus-based treatments for inherited neurological conditions, has closed a $56m series B round co-led by Syncona and Mass General Brigham Ventures, the investment arm of health system Mass General Brigham. The Harvard University spinout has bow raised $133m altogether, after Syncona had already contributed to…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
